Dresden-based healthtech startup developing MyeloAID, an AI-powered bone marrow diagnostic software that analyzes bone marrow samples faster and more precisely, platform-independent and compatible with existing microscopes and scanners. Focused on blood cancer diagnostics and digital biomarkers to improve precision medicine for hematology patients.
Investment Rounds
Capital activity and funding progression
Frequently Asked Questions
Where is Cancilico located?
Cancilico is located in Dresden, Germany.
What industries does Cancilico operate in?
Cancilico operates in the following industries: healthtech, diagnostics, artificial intelligence, biotech.
When was Cancilico founded?
Cancilico was founded on 2026-01-21.
How much total funding has Cancilico raised?
Cancilico has raised a total of $2,500,000.
Who are the investors in Cancilico?
The investors in Cancilico are: High-Tech Gründerfonds (HTGF), TGFS - Technologiegründerfonds Sachsen, GEDAD GmbH, ROI Verwaltungsgesellschaft (Roland Oetker).
Who are the founders of Cancilico?
The founders of Cancilico are: Markus Badstübner, Dr Moritz Middeke, Tim Schmittmann, Sebastian Riechert, Dr Jan Eckardt, Dr Karsten Wendt, Prof. Gerhard Ehninger, Dr. Moritz Middeke, Dr. Jan Eckardt, Dr. Karsten Wendt.